Product Overview

Ostistem is RCT’s lead regenerative medicine product, derived from human umbilical cord–sourced Mesenchymal Stem Cells (MSCs). It is designed to address the underlying pathological mechanisms of joint degeneration rather than providing only symptomatic relief.

By leveraging the immunomodulatory and regenerative properties of MSCs, Ostistem aims to reduce inflammation, support cartilage repair, and improve overall joint function and patient mobility.

Mechanism of Action

Ostistem exerts its therapeutic effect through multiple complementary biological mechanisms:

• • Modulation of inflammatory pathways within the joint microenvironment
• • Secretion of bioactive factors that promote cartilage repair and tissue regeneration
• • Regulation of immune cell activity to prevent progressive joint damage
• • Enhancement of local healing responses and tissue homeostasis

Cell Source & Manufacturing

Ostistem is derived from ethically sourced human umbilical cord tissue, selected for its high proliferative capacity, immunomodulatory profile, and low immunogenicity.

The product is developed using standardized and scalable manufacturing processes designed to ensure consistency, safety, and quality across production batches, in alignment with global regulatory and quality guidelines.

Potential Therapeutic Indications

Ostistem is being developed for conditions characterized by joint inflammation and cartilage degeneration, including but not limited to:

• • Osteoarthritis and degenerative joint disorders
• • Inflammatory joint diseases
• • Cartilage injuries and joint wear-related conditions
• • Mobility impairment associated with joint degeneration

Key Advantages

• • Targets disease biology rather than symptom management alone
• • Combines anti-inflammatory and regenerative effects
• • Derived from a non-invasive, ethically sourced tissue
• • Potential for long-lasting improvement in joint function